Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

This article was originally published in PharmAsia News

Executive Summary

Just days after Seattle Genetics lost Roche/Genentech as a partner for dacetuzumab (SGN-40), a CD40 antibody in development for lymphomas and multiple myeloma, the company has a new Big Pharma partner to head into the new year with. Seattle Genetics and Takeda's Millennium oncology unit announced a licensing deal Dec. 15 for brentuximab vedotin (SGN-35), an antibody-drug conjugate in development for lymphomas

You may also be interested in...



Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance

Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.

Takeda Shifts Resources In U.S. For "Promotionally Sensitive" Brands

TOKYO - Takeda Pharmaceutical Feb. 3 reported a 53.7 percent net earnings jump for the April-December 2009 period from the same period a year ago as it was released from the drag of its Millennium Pharmaceutical acquisition costs, but - as has affected all Japanese pharma - sales of its core projects were generally soft because of the yen's rise against the U.S. dollar

Takeda Shifts Resources In U.S. For "Promotionally Sensitive" Brands

TOKYO - Takeda Pharmaceutical Feb. 3 reported a 53.7 percent net earnings jump for the April-December 2009 period from the same period a year ago as it was released from the drag of its Millennium Pharmaceutical acquisition costs, but - as has affected all Japanese pharma - sales of its core projects were generally soft because of the yen's rise against the U.S. dollar

Related Content

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel